39,502 Shares in InMode Ltd. (NASDAQ:INMD) Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 39,502 shares of the healthcare company's stock, valued at approximately $660,000. Fox Run Management L.L.C. owned about 0.06% of InMode at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. State Street Corp raised its position in shares of InMode by 3.7% in the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock worth $34,657,000 after purchasing an additional 73,183 shares during the last quarter. Geode Capital Management LLC raised its holdings in InMode by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,101,951 shares of the healthcare company's stock worth $18,678,000 after buying an additional 6,282 shares during the last quarter. Systematic Financial Management LP grew its holdings in shares of InMode by 13.3% during the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company's stock valued at $16,647,000 after buying an additional 115,492 shares during the last quarter. Disciplined Growth Investors Inc. MN grew its holdings in shares of InMode by 0.4% during the third quarter. Disciplined Growth Investors Inc. MN now owns 808,149 shares of the healthcare company's stock valued at $13,698,000 after buying an additional 3,191 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its holdings in InMode by 12.9% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 720,750 shares of the healthcare company's stock worth $12,217,000 after acquiring an additional 82,100 shares during the last quarter. 68.04% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts have commented on INMD shares. Barclays increased their target price on InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $22.25.

InMode Stock Performance

Shares of NASDAQ INMD traded down $0.60 during midday trading on Friday, hitting $17.70. 1,447,163 shares of the stock traded hands, compared to its average volume of 1,161,500. InMode Ltd. has a one year low of $14.87 and a one year high of $21.76. The firm has a market capitalization of $1.23 billion, a P/E ratio of 7.53 and a beta of 2.08. The firm has a 50-day moving average of $18.32 and a two-hundred day moving average of $17.77.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.